{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:55:29Z","timestamp":1790470529142,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jgar.2020.06.001","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T01:05:15Z","timestamp":1591837515000},"page":"713-717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Comparative in vitro activities of meropenem in combination with colistin, levofloxacin, or chloramphenicol against Achromobacter xylosoxidans strains isolated from patients with cystic fibrosis"],"prefix":"10.1016","volume":"22","author":[{"given":"Damla","family":"Damar-\u00c7elik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"N\u00f8rskov-Lauritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna","family":"\u00d6zbek-\u00c7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2020.06.001_bib0005","series-title":"Manual of clinical microbiology","first-page":"1384","article-title":"Miscellaneous gram-negative bacteria","author":"Pickett","year":"1991"},{"key":"10.1016\/j.jgar.2020.06.001_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0195-6701(88)90115-6","article-title":"Outbreak of infection with Achromobacter xylosoxidans from contaminated intravascular pressure transducers","volume":"12","author":"Gahrn-Hansen","year":"1988","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.jgar.2020.06.001_bib0015","doi-asserted-by":"crossref","first-page":"562","DOI":"10.12659\/AJCR.896577","article-title":"Sepsis caused by Achromobacter xylosoxidans in a child with cystic fibrosis and severe lung disease","volume":"17","author":"Stobbelaar","year":"2016","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.jgar.2020.06.001_bib0020","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s10096-011-1182-5","article-title":"Achromobacter xylosoxidans respiratory tract infection in cystic \ufb01brosis patients","volume":"30","author":"Lambiase","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2020.06.001_bib0025","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jcf.2012.10.002","article-title":"Identification and distribution of Achromobacter species in cystic fibrosis","volume":"12","author":"Spilker","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jgar.2020.06.001_bib0030","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jcf.2015.09.005","article-title":"Use of nrdA gene sequence clustering to estimate the prevalence of different Achromobacter species among cystic fibrosis patients in the UK","volume":"15","author":"Coward","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jgar.2020.06.001_bib0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10096-008-0605-4","article-title":"Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients","volume":"28","author":"Spicuzza","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2020.06.001_bib0040","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1128\/JCM.05283-11","article-title":"Achromobacter xylosoxidans: characterisation of strains in Brazilian cystic fibrosis patients","volume":"49","author":"Pereira","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2020.06.001_bib0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jcf.2006.05.011","article-title":"Achromobacter xylosoxidans infection in cystic fibrosis: prevalence and clinical relevance","volume":"1","author":"De Baets","year":"2007","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jgar.2020.06.001_bib0050","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1017\/S0950268816002624","article-title":"Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis","volume":"145","author":"Pereira","year":"2017","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jgar.2020.06.001_bib0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0958-1669(03)00036-3","article-title":"Gene transfer occurs with enhanced efficiency in biofilms and induces enhanced stabilisation of the biofilm structure","volume":"14","author":"Molin","year":"2003","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.jgar.2020.06.001_bib0060","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00284-012-0213-5","article-title":"Achromobacter xylosoxidans: an emerging pathogen carrying different elements involved in horizontal genetic transfer","volume":"65","author":"Traglia","year":"2012","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.jgar.2020.06.001_bib0065","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/JCM.39.11.3942-3945.2001","article-title":"Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis","volume":"39","author":"Saiman","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2020.06.001_bib0070","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jac\/26.6.857","article-title":"The in-vitro susceptibility of Alcaligenes denitrificans subsp. Xylosoxidans to 40 antimicrobial agents","volume":"26","author":"Rolston","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2020.06.001_bib0075","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jcf.2013.04.013","article-title":"Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis","volume":"12","author":"Wang","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jgar.2020.06.001_bib0080","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3109\/00365548.2012.664780","article-title":"Clinical and microbiological evaluation of eight patients with isolated Achromobacter xylosoxidans","volume":"44","author":"Atalay","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jgar.2020.06.001_bib0085","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1099\/jmm.0.000499","article-title":"Prevalence and species distribution of Achromobacter sp. Cultured from cystic fibrosis patients attending the Aarhus centre in Denmark","volume":"66","author":"Gade","year":"2017","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jgar.2020.06.001_bib0090","series-title":"M100-S24. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fourth Informational Supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2014"},{"key":"10.1016\/j.jgar.2020.06.001_bib0095","series-title":"Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guideline M26-A","author":"National Committee for Clinical Laboratory Standards (NCCLS)","year":"1999"},{"key":"10.1016\/j.jgar.2020.06.001_bib0100","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/clinids\/4.2.294","article-title":"Synergistic combinations of antibiotics in gram-negative bacillary infections","volume":"4","author":"Klastersky","year":"1982","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.jgar.2020.06.001_bib0105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijantimicag.2009.08.015","article-title":"In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods","volume":"35","author":"Almuzara","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2020.06.001_bib0110","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1099\/jmm.0.000801","article-title":"In vitro activity of \u03b2-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis","volume":"67","author":"Mathy","year":"2018","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jgar.2020.06.001_bib0115","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/clinids\/23.3.569","article-title":"Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature","volume":"23","author":"Duggan","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2020.06.001_bib0120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1055\/s-0034-1396929","article-title":"Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies","volume":"36","author":"Abbott","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2020.06.001_bib0125","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment of lung infection in patients with cystic fibrosis: current and future strategies","volume":"11","author":"D\u00f6ring","year":"2012","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jgar.2020.06.001_bib0130","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2020.06.001_bib0135","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1159\/000321015","article-title":"Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii","volume":"56","author":"Ozbek","year":"2010","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jgar.2020.06.001_bib0140","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/jac\/dku065","article-title":"In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates","volume":"69","author":"Gaibani","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2020.06.001_bib0145","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1128\/AAC.00065-10","article-title":"The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression","volume":"54","author":"Louie","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2020.06.001_bib0150","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJM197105132841904","article-title":"Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia","volume":"284","author":"Schimpff","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2020.06.001_bib0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijantimicag.2004.10.002","article-title":"Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli","volume":"25","author":"Sader","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2020.06.001_bib0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0732-8893(01)00281-4","article-title":"In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations","volume":"41","author":"Krueger","year":"2001","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520301442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716520301442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T16:21:43Z","timestamp":1608394903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716520301442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":32,"alternative-id":["S2213716520301442"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2020.06.001","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative in vitro activities of meropenem in combination with colistin, levofloxacin, or chloramphenicol against Achromobacter xylosoxidans strains isolated from patients with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2020.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}